Show Notes
🎙️ Powered by THC Group, Policy, Decoded is the Sunday briefing that steps back from the churn and unpacks one consequential policy story shaping cannabis, hemp, alcohol, and regulated markets. This week, we examine the structural failure underneath the legal cannabis market's most important promise. Everyone agrees that testing matters. Legislators say it. Regulators build their frameworks around it. Operators absorb the cost. Voters feel reassured by it. That consensus has held from the earliest days of legalization through every state that followed. It has also, on its own, not been nearly enough. Since January 2023, at least eleven testing laboratories have faced formal enforcement action across six states. In Michigan, a lab that tested 60 percent of the state's cannabis was permanently shut down after technicians classified visible mold as mite feces. In Massachusetts, a lab reported yeast and mold failure rates ninety times below the statewide average. In California, a lab director signed a certificate of analysis clearing a product that contained a banned pesticide at 600 times the permissible level. In Oregon, seven of the state's eleven accredited labs were cited simultaneously, three for adding kief directly to testing samples. This episode walks through what that record reveals about two distinct structural vulnerabilities in cannabis testing. The first is lab shopping, where operators seek the lab most likely to return favorable results. The second is less discussed and may be more consequential: in most states, operators select their own compliance samples. When sampling is compromised, even excellent laboratory work cannot protect patients. We explore why potency inflation gets the headlines but contamination failures carry the real clinical risk, how testing costs and affordability gaps push vulnerable patients toward the unregulated market, why the emerging state reference lab movement risks replicating fragmentation rather than building shared standards, and what the repeal campaigns gathering strength in Massachusetts and elsewhere are doing with the testing record. The legal cannabis market built its entrance on a safety promise. The testing system underneath that promise was designed with structural flaws that most states have not corrected. The opposition does not need to manufacture a crisis. The testing record is assembling one. The question is whether the industry and its regulators fix it before someone else uses the evidence to take the whole project apart. 🔗 Read the full Sunday editorial Sign up for Policy, Decoded This podcast may include content written or produced with the support of AI tools under human direction and editorial oversight.
More from Policy, Decoded
An eighth of cannabis costs $15 in Washington and $52 in Kentucky, where every buyer is a patient. A bottle of bourbon costs about the same in all fifty states. We run the experiment the other way and ask what happens if bourbon can't cross a state line, then follow four states that never traded a gram to the same $18 price. We look at who pays in an open market and who pays under a cap. The former regulator's bottom line: most of what a state charges above $18 is a decision somebody made.
🎙️ Powered by THC Group, Policy, Decoded steps back from the churn to unpack one policy story shaping cannabis, hemp, alcohol, and regulated markets. This week: on the drive to a dispensary you pass plate readers at the pharmacy, the bank, and the hardware store, and the only one any government required is the one pointed at people buying cannabis. We say plainly where we land, and it implicates us to say it: we wrote those camera rules, we would write most of them again, and we never wrote the sentence about who gets to search the footage. So we walk a Wisconsin criminal complaint that treated a lawful trip to Michigan as grounds for suspicion, the Illinois statute that banned out-of-state queries and forgot the penalty, and a Texas search that reached more than eighty thousand cameras and left a record only because a company keeps an audit log by choice. We run last week's product announcement against the Wisconsin case and watch it pass every new control. And we trace the Massachusetts rule that already got this right for one narrow class of footage, and the doorstep reasoning that says it should reach further. The former regulator's bottom line: the requirement was never the mistake, and leaving it where it sits would be. 🔗 Read the Sunday editorial This podcast may include content written or produced with the support of AI tools under human direction and editorial oversight. Sign up to receive Policy, Decoded in your inbox
🎙️ Powered by THC Group, Policy, Decoded steps back from the churn to unpack one policy story shaping cannabis, hemp, alcohol, and regulated markets. This week: the Senate tabled the hemp amendment at two in the morning, an entire market got a crash course in civics on the way out, and fire drills only reward the people who practiced. We say plainly where we land, and it costs us something to say: the most effective advocate is the person actually affected, almost never the professional, and this publication is paid to be the professional. So we unpack a career spent on the receiving end of lobbying, the survey in which nearly nine in ten career EPA staff admitted a story moved them, the eighty percent of federal dockets that draw ten comments or fewer, and the Colorado rulemaking where hearing testimony ranked dead last because the rules were settled months earlier in workgroups. We trace Tip O'Neill's neighbor who wanted to be asked, and the North Carolina hemp businesses who watched their own senator lead the charge against them. The former regulator's bottom line: the quiet years are where the leverage lives, and you are the one a policymaker will remember. 🔗 The Power of Presence: A Guide to Policy Advocacy This podcast may include content written or produced with the support of AI tools under human direction and editorial oversight. Sign up to receive Policy, Decoded delivered daily to your inbox.
🎙️ Powered by THC Group, Policy, Decoded steps back from the churn to unpack one policy story shaping cannabis, hemp, alcohol, and regulated markets. This week: the DEA's rescheduling hearing is over, the evidence is in, and the file it produced will matter longer than the headlines about it. For two and a half weeks, in a sealed hearing room with no cameras and a handful of public seats, the government argued under oath that cannabis belongs in Schedule III, and seven designated opponents argued back. We read the file the way a former regulator would. A government case that reversed fifty years of institutional position in a single morning, on the record for good. An opposition that put DEA's own scientist on the stand and watched its marquee witness concede the statutory question in a five-minute cross. And the 1988 precedent every operator should know: the judge who read the record most closely lost to the administrator who signed the order. The recommended decision is advice, the transcript is the document, and the real audience sits at the D.C. Circuit. The people who built this industry did their part without a hearing. The least the process can do is finish. 🔗 Read the Sunday editorial This podcast may include content written or produced with the support of AI tools under human direction and editorial oversight. Sign up for Policy, Decoded.
🎙️ Powered by THC Group, Policy, Decoded steps back from the churn to unpack one policy story shaping cannabis, hemp, alcohol, and regulated markets. This week: after fifty years of calling cannabis dangerous and useless, the federal government has to stand up in a courtroom and argue the opposite, and the reform is overdue, right, and far easier to lose than anyone wants to admit. For fifty years the federal case against cannabis fit in a single sentence: dangerous, useless, Schedule I, filed next to heroin. On Monday, in a hearing room in Arlington, the same government has to prove the reverse, that the plant is medicine. We say plainly where we land. It is right, and it is fifty years overdue. The question is not whether it happens. It is whether the government can do the overdue thing without losing it on a technicality, or breaking the people who built the industry on the way in. So we unpack what the hearing actually is, dull administrative procedure, stacked with only opponents, deciding nothing by itself, and where the real fight has already gone, across the river to the D.C. Circuit, where April's medical reschedule is under challenge for the very shortcut that made it fast. We trace the shockwave already loose in the market, medical now in Schedule III and adult-use still in Schedule I, a fault line cutting through the same companies, the same shelves, the same customers. And we land where the rule never will, on the budtender, the grower, and the family that signed a personal guarantee, the people a Schedule III order will reach and never name. The former regulator's bottom line: a decision you cannot defend on appeal is just a reversal with a delay on it, and the fastest way to lose this reform is to win it badly. 🔗 Read the Sunday editorial This podcast may include content written or produced with the support of AI tools under human direction and editorial oversight. Sign up for Policy, Decoded.